Alhamdulliah, officially graduated from the Internal Medicine Residency training from Northwest Healthcare Tucson. It was a journey that happened with support of my family, friends, colleagues, and my great mentors. #Graduation #Internalmedicine #ACGME

‼️ #EHA2026 simultaneous publication by @mattwilson2287 et al:  High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Analysis of 1,923 Patients Read the full article: bit.ly/4efwgue

frontMIND: a new first-line regimen for high-risk DLBCL? The phase III frontMIND trial (Lenz et al., Lancet) adds tafasitamab (an Fc-enhanced anti-CD19 antibody) lenalidomide to R-CHOP, in 899 patients with high-intermediate or high-risk DLBCL/HGBL (IPI 3-5 or aaIPI 2-3). The results: → Improved PFS: HR 0.75 (0.59-0.96), p=0.019 — 2-year PFS 71% vs 63% ( 8.2 points) → Benefit driven by the ABC subtype (HR 0.59), more modest in GCB (0.69, CI crossing 1) → OS still immature, no significant difference (HR 0.85) → The price to pay: more hematologic and infectious toxicity, treatment-related mortality 6% vs 4% (partly COVID-related, as the trial ran during the pandemic) The comparison with POLARIX is tempting, but should be handled with caution: no head-to-head data, and populations that resemble each other without overlapping — frontMIND enrolled higher-risk patients (IPI 3-5, 31% ECOG 2, vs IPI 2-5 and 16% in POLARIX). At their core, the two stories echo each other: near-identical PFS HRs (0.75 vs 0.73), absolute benefit of the same magnitude, a clear signal in ABC, nothing convincing in GCB, and no demonstrated overall survival benefit. That said, pola-R-CHP replaces vincristine without meaningfully adding to the toxicity profile, whereas tafa-len-R-CHOP adds two drugs and a weekly tafasitamab schedule, at the cost of what appears to be higher toxicity. A question common to both trials: in the absence of an overall survival benefit, what place in our treatment algorithms? #DLBCL #lymphoma #hematology thelancet.com/journals/lance…

The CD123-directed antibody-drug conjugate pivekimab sunirine-pvzy is now approved for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). A meaningful advance in a rare leukemia subtype, with important contributions from Dr. Naveen Pemmaraju and Dr. Naval Daver. spr.ly/6012B8di3k @doctorpemm @Daver_Leukemia #EndCancer

Excited to share our new paper on patient-reported time toxicity with bispecific antibodies (mosun, glofi, epco) in R/R FL and DLBCL @OncJournal. A few key points from our study, including impacts on time tox research & patient-centered #lymsm care: 🧵 academic.oup.com/oncolo/adva…

CD3xCD20 BsAb secondary CNS lymphoma (CUBIC Consortium) - 28 pts, most glofi, 64% active CNS dx, 64% prior CAR - active CNS: ORR 56% (CR 33%), CNS ORR 65% (CR 35%), 6-mo PFS 43% (CNS-PFS 53%) - no PD among pts achieving CR - responses in LM dx & post-CAR - 25% ICANS (incl G3-4) Encouraging activity as monotherapy (combo regimens no better). #lymsm nature.com/articles/s41408-0…

This is interesting, so CNS prophylaxis didn’t reduce the relapse in the cohort.

Review series on clonal hematopoiesis: how should clinicians approach clonal hematopoiesis in practice? This review outlines current strategies for risk assessment, monitoring, and clinical decision-making. haematologica.org/article/vi…

Dara-VCd vs. VCd: ANDROMEDA Final Survival Analysis. Dara-VCd associated with higher hematologic CR (59% vs. 19%), organ responses, PFS (HR: 0.44) and OS (HR: 0.62) #mmsm #amyloid @BloodPortfolio ashpublications.org/blood/ar…

I don’t tweet much so I’ll keep this simple We are looking to recruit 1-2 new postdoctoral fellows, to study human hematopoietic development, from both basic and translational perspectives, using iPSCs. Please reach out via email for more details if interested!

Excited to attend Stanford’s BMT & CAR-T Symposium and learning from experts across the country. The symposium provided valuable insights into the current landscape and future developments in malignant hematology. #MaligHem #Lymphoma #MM #Leukemia #CART #ASCT #AlloCART #ORCA-T

Good luck to everyone waiting on their Internal Medicine match results! You have survived the endless UWorld blocks, and the gauntlet of interviews. Whether you end up matching or not, remember that your hard work have already proven you are ready for this. #Match #Match2026

Congratulations to Dr. Negrin on the life time achievement award.

Prayers for Jamaica!

I am excited to share that I have cleared American Board of Internal Medicine. I am thankful to everyone for their support in this journey that started from my hometown Zhob and transitioned to being a Diplomat in ABIM. #ABIM #Internalmedicine

Such a tragic loss, prayers for the family.

Good luck to all the applicants for the residency match 2026. Your hard work, consistency, and dedication will pay off. #Match2026 #Residency #ACGME

Olanzapine, when tolerated (I usually dose escalate from 2.5 mg) should be standard for cachexia, appetite, nausea. Still seeing megace, mirtazapine recommended despite essentially no evidence. We need more supportive onc education for our hem inc practitioners and fellows.

🚨 ESMO 2025 Lymphoma Guidelines - Less chemo ➝ More precision. A complete update across 7 lymphoma subtypes 🧬 🔵 DLBCL • Pola-CHP (IPI ≥2, fit <80 yrs) • CAR-T in early relapse • Bispecifics in ≥2L r/r 🌿 FL • ISRT (24 Gy) curative in stage I/II • Watch & wait in low-burden disease • CAR-T, bispecifics, tazemetostat in later lines 🌀 MCL • BTKi-integrated induction (preferred) • MRD-guided ASCT omission if uMRD by clonoSEQ • CAR-T & pirtobrutinib post-BTKi 🔥 HL • BrECADD (≤60 yrs) frontline • Nivo-AVD (60–80 yrs) frontline • BV or PD-1 inhibitor (Nivo/Pembro) in r/r 🧠 PCNSL • MATRix induction (HD-MTX based) • Thiotepa-ASCT consolidation • Avoid WBRT in elderly • Low-dose WBRT in select CR patients 🍋 MZL • H. pylori eradication (gastric EMZL) • ISRT for localized • Immunotherapy or BR in advanced/relapsed ⚡ PTCL • BV-CHP = standard for ALK– ALCL • CHOEP alternative • ASCT consolidation in responding PTCL NOS/TFHL ✨ Takeaway: Shift towards chemo-free, precision, & immunotherapy-driven care. 📓Eyre TA, Cwynarski K, d’Amore F, et al. Ann Oncol 2025. 🔗DOI: doi.org/10.1016/j.annonc.202… #OncoTwitter #MedTwitter #Lymphoma #Immunotherapy @OncoAlert @myesmo @asco

Excited to join the GME diversity committee of @StanfordMed. It’s a pleasure to connect with fellows and residents with diverse backgrounds, practicing medicine. @StanfordODME @LahiaYemaneMD

This is exciting news